FDA Grants Approval for HDT Bio's Groundbreaking Vaccine Against Tick-Borne Diseases HDT Bio's HDT-321 vaccine receives FDA approval, targeting the deadly Crimean-Congo Hemorrhagic Fever, marking a significant advancement in biodefense.

FDA Grants Approval for HDT Bio's Groundbreaking Vaccine Against Tick-Borne Diseases #United_States #Seattle #HDT_Bio #CCHF #HDT-321

MalarVx Partners with HDT Bio to Create Advanced Malaria Vaccine Utilizing Cutting-Edge Technology MalarVx, Inc. has partnered with HDT Bio to develop a new malaria vaccine using their innovative repRNA technology, aiming to combat a global health crisis.

MalarVx Partners with HDT Bio to Create Advanced Malaria Vaccine Utilizing Cutting-Edge Technology #United_States #Seattle #HDT_Bio #MalarVx #Malaria_Vaccine